I've noticed a lot of new people in here asking some obvious questions to those of us who have been around for a while. So to generate new and better discussion I want to answer some of these frequently asked questions.
 
1. Where can I find information about these companies
I hope you haven't bought any of these names before you did research and before you even know where to start looking. First place you should go to is Google and type in " investor relations". If this is too much you can shorten it to " IR". It should be the first link in every case and if it's not then that's already a red flag.
Read about the companies products, how they operate. Read their MD&A, read their financial statements from the last few years. Maybe look at product reviews or review the products yourselves. Watch interviews with the CEO. Find out what makes this company unique, operationally effective and worth buying for consumers. You should quickly figure out that APHA is NOT a cannabis company, but a consumer packaged good company. They own Cannabis, Alcohol, and Pharma businesses (plus hemp after the TLRY merger).
Doing your DD should take time. Don't be in a rush to buy the stock because it's run up 100% in the past few weeks. If you look at the chart, 2 years ago these companies rocketed upwards to ATHs, you could have waited another year or so and bought lower. Are we taking off to the moon and never coming back? Probably not.
 
2. Where can I buy these companies? Are they on Robinhood?
First, ditch Robinhood a get a broker that won't go under in the next few years. Pay a trading fee if you need to but just buy enough stock to make the tade worth it. Don't buy $20 of Apha on investorline or you're immediately taking a 50% haircut with a $9.95 trading fee.
Second, you can buy these companies on most/all legit trading platforms. I won't name them all but all of the big Canadian banks self-directed platforms have them. I'm not American so I can't speak for them but I've heard good things about Fidelity and Vanguard.
Oh, did you also mean what exchanges can I buy them on? Big Canadian names are on the major exchanges like TSX and Nasdaq. Smaller names are on the CSE and OTC markets. US names can't list on the big exchanges because your government decided cannabis was bad like 50 yrs ago so those are only on the OTC and CSE markets. MSOs is a fund on the NYSE (I think) that hold some sort of swaps on the US names but I personally just buy the names myself. Again, do you own DD, even if you're buying a fund.
 
3. This stock went up x% in the last y time, should I buy it or wait for a dip?
This ties into point 1 above, so if you've done your DD you should know if the company is worth what it is priced at. The market does wacky shit all the time (see Gamestop, morgage crisis, great depression) so it'll go up and down, but generally follow along the trajectory of the company profits. If the profits increase by 5x in 10 years, the stock price will do the same. If you're asking for predictions in the short term consult a fortune teller, roll dice or find one of those pets that pick stocks.
 
4. What stocks should I buy? How do you feel about x company?
See 1, then 3. I can't tell you what companies are good in the space better than your own research. Especially since you don't know what my plans are. Maybe a poster says buy "Apha" but they're only holding until the TLRY merger closes. They'll never tell you when they're selling so if it drops you'll be scratching your head. Do a bunch of research on the main players, then some smaller guys and figure out what you can stomach. Maybe a cannabis ETF is right for you or maybe 1 or 2 strong picks or maybe you like gambling with penny stocks. Just do your own DD.
Popular names and good places to start are:

• Canadian names: APHA/TLRY, CGC/WEED, ACB, CRON
  
• US names: CURA, TRUL, CL, GTII
  

 
5. Should I buy leaps or warrents or calls or puts? Also what are derivatives?
If you have to ask, no. I'm also not going to explain because I don't know either.
 
6. I bought Gamestop at all time highs and I sold and lost 90%, is cannabis good?
No, kindly take your paper hands and go back to WSB. We don't want investors in this space who sell at the first 10% drop after an 100% run, or after a 50% drop from ATHs, or after a short report from some short selling parasites. We hold because this is a once in a lifetime opportunity of a product moving from the illicit market to the legal market. There is no need to build up demand, merely move the consumer from buying from their dealer to our dealer. This will take time, regulatory changes, perception changes and most importantly, your patience.
 
7. Any small companies you can reccomend?
Being a small company in this space comes with distinct disadvantages. Price compression in Canada will kill small/medium sized growers since they can't achieve postive margins without scale. Add in some mould on even 1 harvest and the losses have destroyed your business. On the US side, regulations are weird and vary across different states. Califonia is a dumpster fire, Florida requires you to be vertically integrated, and other states have limited licences for retail and grows. Think about how hard it would be to get a foothold in Florida as a small business. Think about how valuable a licence is in limited licence states. Maybe your small player is looking for licences and gets NONE. That's devastating. Curaleaf misses 1 licence? Not great, but they have other applications in multiple states.
If you're buying a small company or penny stock, know the risks and do extra DD.
THERE HAVE BEEN COMPANIES THAT ARE FRAUDULENT IN THIS INDUSTRY.
COMPANIES HAVE GONE BANKRUPT IN THIS INDUSTRY.
Canntrust was legit but had fake walls with more plants behind them. Ignite was run by Dan Bilzerian. YOUR PICKS ARE NOT IMMUNE FROM GOING BANKRUPT.
Let me repeat the most important point: THERE HAVE BEEN COMPANIES THAT ARE FRAUDULENT IN THIS SPACE.
 
8. I wanna buy because of US legalization! When will Cannabis be legalized in the US?
Asking for a specific date is dumb and assuming that it's going to pass is dumber. Yes, Democrats control all 3 branches of government and yes, they are more cannabis friendly than Republicans and yes, some Republican states also recently legalized cannabis. THIS DOES NOT MEAN LEGALIZATION WILL PASS THIS YEAR, OR EVEN UNDER THIS CONGRESS OR PRESIDENT. Some Republicans in the house voted for cannabis regulation under Trump and some Democrats voted against it. We have no idea how the senate will vote and it doesn't take many votes to torpedo any legislation.
If you know the US Cannabis space right now you'll know that descheduling and getting access to lower tax rates, access to capital and ability to cross state lines are some of the most important regulatory changes that need to happen. Look up the 208e280e tax code. Seriously do it. Full legalization is nice but also unlikely.
 
If I've missed any questions post them below. and I'll add them.
 
TL:DR: Do your own DD. Start here:

• Canadian names: APHA/TLRY, CGC/WEED, ACB, CRON
  
• US names: CURA, TRUL, CL, GTII
  

 
EDIT: Adding in some resources for those who want more. These are my own resources I use/used to get started. If you have resources to share please do so but don't self promote you ding dongs.
 
Resources
New to Investing:

• Most people think Warren Buffet is the GOAT but Peter Lynch is also a GOAT in his own right and a better speaker.
• People also think you need to read through all of "The Intelligent Investor" before you can start investing but that's bs. Read "One up on Wallstreet" by Peter Lynch. It's like 300 pages shorter and more fun. Then read Intelligent Investor if you want but if you get 20 pages in and fall asleep or feel stupid then I told you so.
• Martin Shkreli is an asshat but he knows the finance side of valuing companies. His finance lessons are awesome if you stand him for a few hours at a time. Follow along with your own companies.

Cannabis Resources:

• The sidebar has great resources. Stateside cannabis investors(EDIT: Currently down) is awesome for the US side.
• The OCS releases a quarterly report you should read for Canada. Hell, go to OCS.ca and see what products are available and prices. Go to the BC page, the quebec page etc...
• Statscan has a cannabis hub. It's updated super rarely and it might be archived but it's good to look at to start.

I'm building a free and open source software that will enable people to easily search and build metrics using the posts and comments on /wallstreetbets. Basically, the software will analyze the posts and comments, let people easily understand the sentiment of the community and take positions accordingly.
Github: https://github.com/steve-care-software/products
Here's why:
In the past, the stock market was heavily used by professional stock traders like hedge funds, equity funds, etc. Now a days, technology has evolved so that retail investors can easily trade in the market.
This brings people that calculate things differently in the market. Professional stock traders are used to analyze the market and try to discover future prices using past data. When a company doesn't have good fundamentals, professional stock traders are used to short the stock and kill the company.
However, sometimes, companies have plans to turn their company around. Retail investors are a bit more emotional: they are the customers of the companies and sometimes are emotional when it comes to company they like.
Recently, GameStop (GME) decided to turn their company around. They had a lot of debt, very few professionals wanted to lend them the money they needed to execute their plan. However, when they released to the public, retail investors liked. They wanted GameStop to execute that plan and be customers in their updated company.
Hedge funds decided, however, that the plan was not as good. They didn't listened to the future customers of GameStop, the retail investors, and decided to short the GME stock.
Retail investors continued to buy, while hedge funds continued to short it. Hedge funds gambled so much that they executed short position at 140% of the available float, thinking that retail investors would sell due to the pressure.
This never happened. Retail investors kept buying. It created a short squeeze and made the GME stock sky rocket.
People in mainstream media are currently talking that the /wallstreetbets community manipulated the market. In my book, they are saying that because they don't understand that the stock markets are currently evolving. In the future, hedge funds will need to analyze the sentiment of future customers when a company with bad fundamentals try to spin their company.
However, I think regulators will try to shut the WSB community down. Therefore, I want to protect it by making it impossible to shut down. On top of that, I also want to build the tools to further help retail investors understand the market and protect the company they like.
If you like the idea, please share this subreddit with people on reddit. Ill update every day with my progress. If you have any question, please ask them. Ill be around every 4 hours during day time.
I'm located in Quebec, Canada.

I recently wrote this up for my friends who asked me how I do what I do. I figured I'd share it here. This is freely available to anyone who wants it, though please credit me if you simply copy/paste. Nothing here is novel, and can be done by anyone. I am not a financial professional, and the example given below is only Abbvie because I forgot that Abbott Labs was alphabetically the first in the S&P 500 when picking an example.
​
First, let’s come right out and say that if you do not have the time to do this, or do not find it enjoyable, just buy low-cost index funds that track either the total market or the S&P 500.
Second, let’s make an important distinction:
Investing – This is the act of purchasing assets for less than their intrinsic value. This PDF will focus on how to determine the intrinsic value of an asset that produces income. Note that for most assets, this is simply how much money you can extract from the asset over the period of time that you hold it for. There’s no other value than money in investing. Causes and emotions are what philanthropy is for.
Speculating – This is, at its core, the act of taking supply of an asset from the present to the future (by hoarding it). If there is more demand, lower supply, or both, this pays the speculator to take the asset from a period of low value to one of high value. It is not gambling, but is very difficult to do, since it entails taking on timing risk. It is not illegal, immoral, or impossible, but I have no special insight into it. I’ll leave it there.
Gambling – This looks a lot like speculation, but without any particular reason to believe the asset will be more valuable in the future. Speculators at least estimate the value of an asset to investors, as they are ultimately the end market for an asset. Do not gamble. Full stop.
Determining the intrinsic value of an asset
The value of an asset is simply the present value of all future income that asset can provide you. Since a dollar in five years is naturally less valuable than a dollar today, you have to discount future income against the opportunity cost of forgoing the dollars you invest today. When we get to the Present Value equation, this is represented by interest. It can also be thought of as the opportunity cost of investing in the asset instead of some other asset or simply consuming the dollars instead.
Here’s the actual math. Note that it’s not super hard, and while I will explain it, there are dozens of free websites that will quickly let you calculate this. The key phrase to Google would be “present value of a growing annuity calculator.”
PV = (C / i - G) * {1 – [(1 + G)/(1 + i)]^n}
PV = present value
C = cash flow per period
n = number of payments
i = interest rate
G = growth rate
The value for PV is your estimation of what the asset is worth today. If this ends up far higher than the market price, you are probably purchasing dollars for quarters. Avoid edge cases, as you are guessing about both the interest and growth rate.
C is the cash flow per period. If you have a high degree of confidence in the culture of the company and it has a long history of being good stewards of retained earnings, you can use the earnings per share (EPS). I usually use the dividend. It is impossible to fake or financially engineer a dividend, and requires less looking through financial documents to make sure it’s what it appears to be. But for, say, Apple or Microsoft or Chevron, feel free to use the EPS.
The number of payments is how many payments you expect while holding the asset. Dividends in American companies are typically quarterly (though some pay monthly or every six months, so check on that), so every multiple of four would represent one year if you choose to do it that way. If n = 16, then you’re expecting to hold the asset for 4 years. You can also put in a year’s worth of dividends and keep n = years rather than quarters.
I typically do n = 30, since 30 years is both a long time horizon that is realistic, and coincides when I will hit “retirement age.” You will have to decide how far ahead you’re planning. For most people, they are net purchasers of investments while working and net sellers while retired, so keep that in mind. Note that using years instead of quarters will lessen the amount of compounding, and will provide some cushion in case you’re wrong.
Interest is one of the two variables you have to guess at. Typically, one would put what you expect the actual long-run interest rate to average for this investment. Unfortunately, this is really difficult. Instead, I use a rate that represents my opportunity cost. There are any number of relatively safe ways to get a 5% yield on money invested, so I generally use i = 5% to represent that this asset has to perform better than a utility or telecom or real estate investment trust. Feel free to use what you feel is most appropriate for you. A higher interest rate will lower the value of the asset, so high-balling this number will provide some cushion in case you’re wrong.
The second variable you have to guess at is the growth rate. If you’re looking at the dividend, you want to know how fast to expect it to grow over time. If you’re using the EPS for C, then you want to see how quickly the total earnings are growing per share. This is extremely difficult to predict. I recommend taking the 5-year growth rate and halving it. Dividends will also be more predictable here, as most companies pay out far less than they make, which means even if EPS grows slowly, the dividend can still grow quickly for many years after a boom is over for the company. Note that lowering your estimate for G will lower the value of the asset, so low-balling this number will provide some cushion in case you’re wrong.
OK, so let’s walk through an example. I’ll use Abbvie, a biotech/pharmaceutical company. It has a quarterly dividend for the coming year of $1.30/share. Its dividend has an 18.5% growth rate over the last 5 years, and has grown it for the last 7 (it’s only been around for 8 years).
I assumed a growth rate (G) of 7%. I used $5.20 as the starting dividend this coming year and used years for my n = 30. As always, I used i = 5%.
This gave me an estimated present value of 1 share of Abbvie at $197.94. As of writing this, Abbvie shares are trading on the market at $103.43. This looks like a screaming buy, but first let’s look at why I have a high degree of confidence.
Note how the interest was higher than the going rate – I used my “low-risk alternative” as an opportunity cost. Abbvie has an extremely high rate of growth for its dividend, so I took less than half of its current rate. I also calculated annually rather than quarterly, which reduces the impact of high rates of growth. That’s three places in the equation where I consciously lowered the estimated value of a share of Abbvie, and it still came out as a strong buy – spending less about 50c for a dollar!
I do this because even if I’m wrong in some or all of my predictions, I now have quite a bit of room to be wrong and still make money. It’s like how you don’t walk next to a steep cliff, right? You should know how to walk where you want to, but there’s always the small chance something could cause you to slip or put a foot wrong. But if your plan is always to be 5 feet away from the edge of the cliff, the odds are that you’ll not go over the edge even if you fall down.
Many people feel this is over cautious. But let my portfolio speak for itself. I’ve beaten the S&P 500 index fund every year except one since 2008. My brokerage only keeps digital records back to Dec 2015, but the S&P 500 returned 101% since then – with dividends reinvested. My own portfolio has returned 256%.
So caution is still very high reward. In fact, if you just don’t lose, you’ll do better than the vast majority of professional money managers (about 85% of whom cannot even match the index funds).
Due diligence still has to occur
Now, we can’t just go straight out and buy Abbvie – though it’s a high profile company that receives lots of investor and regulator scrutiny so it’s less likely to have a landmine than most. Just to make sure, you’ll want to do the following before buying shares in this company:
-Check the debt load. If the debt is very high, has very high interest rates, or has a lot of it maturing very soon, then this is a yellow flag. It doesn’t mean don’t buy, but make sure you understand the structure of the company’s debt and make sure it won’t impair the company’s earnings going forward. This information is found on the balance sheet. Abbvie has $97.287 billion in long-term liabilities such as debt, pension liability, and deferred taxes. That’s a lot compared to their assets, but they also are owed some money, so it nets out about $90 billion.
-What’s the book value? Book value is fairly low at $8.65/share. This is pretty much the assets minus the liabilities. Abbvie is in a knowledge industry, however, so you shouldn’t expect their main assets to be physical capital that can be sold. It’s mostly organizational or human capital from their workforce, so this isn’t worrying. If Abbvie was, say, a retailer with stores and land and inventory, you’d want this to be much, much higher for the share price. There’s no easy way to judge this one, unfortunately, but it’s good to look it up and you’ll eventually get a feel for it. No red flags here.
-What are the catastrophic risks that even you or I could think of? For a company in the pharmaceutical space, the obvious answer is regulatory and political risk. Regulatory risk is just want it sounds like – more regulation which can be either costly to comply with or lower profits. This does have an upside, which is that it makes it harder for new competitors to enter a market, so I tend to be rather sanguine about regulatory risk. Political risk is much more severe. This is when politicians decide to either confiscate a company, target it specifically rather than the industry it’s in, or other ways in which the government is involved with taking rather than regulating. In Anglo countries (US/UK/Canada/Australia), the rule of law is typically strong enough that this doesn’t happen much, as there is usually some kind of due process. Places like China, Argentina, Russia, and the EU are much more likely to nationalize or otherwise capriciously penalize a company due to the prevailing political winds. Abbvie has a global footprint, but that also means it’s diversified against such risk. It’s headquartered in the US, so it’s unlikely someone will simply take the entire company.
-Payout ratio? Abbvie has a fairly high payout ratio (80% for the last completed fiscal year of 2019), as they have been aggressively growing the dividend. That’s another good reason to input a much lower G than the last few years. That being said, Abbvie has been around for 8 years (it was spun off of Abbott Labs) and has grown its dividend for the last 7 years and has announced it will this coming year as well. The payout ratio is pretty high, but not worrisome. It suggests a fairly mature company that’s now returning cash to shareholders. I’d say this is not nothing, but less than a yellow flag for me. Any company with 95%+ payout ratio is much more vulnerable to a dividend cut.
-Credit rating? S&P gives Abbvie a BBB+ grade for its unsecured debt. This is a slight downgrade because their balance sheet is currently digesting a big acquisition from early 2020 (Allergan). Moody’s gives it a Baa2 rating for unsecured debt. These are both good, solid, investment-grade credit ratings (if you were buying the bonds of Abbvie). This looks great.
-Does it need a genius? Some companies run on all cylinders because they have a genius at the helm – often a founder. But what you want is a company any dummy can run, because sooner or later any dummy will. Don’t plan to invest long-term in companies that require skilled management. Abbvie is fairly diversified and has an OK pipeline of research. They also can buy little biotech companies that invent something but can’t navigate the regulations to bring it to market. So pondering giants are actually a good thing. Means they’re hard to break.
So, given that there was nothing obviously treacherous in our basic due diligence, and the extreme discount at which our example is selling for, this would be one you might want to buy! This is what I do for all the companies I invest in.
Notice that there is no story, no excitement, no narrative, no counting on good or bad management. Emotion has no place in investing. You also will notice that we took every opportunity to reduce the risk of losing your capital by always sandbagging the estimated value of the company. You never want to pick up nickels in front of a steamroller. You want the investment to be so obvious it hits you in the face like a baseball bat. If you’re ever on the fence, don’t do it. You don’t have to hit home runs – just don’t strike out.
You can be even more conservative in your estimates than I am. If, for instance, you used 5% growth rate for Abbvie’s dividend, you’d still get a present value of $148.57/share vs the current market price of $103.43. Similarly, you could use a higher interest rate, which would also lower the estimated present value.
You may have to do this calculation with more companies to find one to buy, but even in a very expensive market like today’s, there is always an opportunity. You don’t even have to look at little companies. There’s around 500 companies in the S&P – just start with “A” and work your way through all of them.
A quick note about further reading: I very strongly urge most people to actually read as little as possible on this subject once they get the basics. That’s not because there’s not more to learn, but because I would sadly say the majority of what I see and hear is actively bad advice. But if you do want to keep up with financial news and books and chat boards, the best thing to do is find out what the historical returns of the person giving advice are.
Since WWII, the long-run return on the S&P 500 has generally been just a bit shy of 10% per year. If someone can’t beat that, year-in-and-year-out, then their advice is worthless. As in, you don’t want to accidentally absorb it. This is, unfortunately, true for most professionals. Over the last 15 years, 92.2% of actively managed funds have underperformed a simple S&P 500 index fund (and they charge you fees for the privilege). Beware anyone selling something. The advice here is given freely
That’s why I made a point of mentioning that I have and regularly outperform the standard fund almost every year. Granted, I don’t have many of the regulatory restrictions a public fund would have, but it shows how useful the advice I’m giving here is. You don’t need anything fancy. You don’t need anything high risk. I’ve done this through two deep recessions and the longest bull market in history.
If you want to learn more about investing in general and where I learned how to do this, you can read Benjamin Graham’s The Intelligent Investor. It was written in the 1930s, so much of the technical information is out of date. Skip over that and just read it for the concepts.
Even easier reading is to go online to Berkshire Hathaway’s website and pull Warren Buffett and Charlie Munger’s annual letter to shareholders. Almost all of them have something useful in them and don’t make you do equations.
I am available for questions in the comments

I have seen (TSX: FIRE) (OTCQX: SPRWF) get a lot of hype the last few days. It has been the second most actively traded stock on the TSX in the last ten days. They also have a ticker that is literally 🔥 and a brand name that is ultimately supreme. I couldn’t think of a bettedouchier name and ticket for a Cannabis company.

Now the question is, should we buy into the hype?

First, what is $FIRE?
$FIRE = the Supreme Cannabis Company produces marijuana under the banner of its wholly-owned subsidiary 7 Acres. They have a 440,000 square Cultivation facility. They also claim to have a robust R&D and genetics program, advance processing and automated packaging capabilities, and is Health Canada licensed for the sale of cannabis 2.0 products. They claim they have emerged as one of the world’s fastest-growing, premium plant driven-lifestyle company by effectively deploying capital to build a diversified portfolio of successful cannabis brands. I personally feel like every Cannabis company says the same thing so that’s nothing new.
Long story short, Supreme grow and hold Cannabis supplies their partners who produce specific products. Their partners are 7Acres, Blissco, Truverra, Sugar Leaf and Hiway (see picture below).
In FY2020, Supreme Cannabis brought +35 cannabis consumer products to 10 provinces across Canada, formed an industry leading sales partnership, maintained a strong wholesale business and completed its first international medical cannabis export.

Here is a screenshot of what each “partner” is licensed to sell and where they can sell it.

​
All of them look like relatively decent partners that produce product and supply it to primarily Canada. They got licensed in 2019 to sell cannabis oil, weird that the stock dropped so much after that. Weed stock hype died down the last year I think, but with the resurgence I feel like this stock is in a decent position.
Summary: Looks pretty run of the mill, nothing revolutionary, nothing bad. At least they have partners, a product and a decent grow operation.

Financials:

​
https://preview.redd.it/zw8ze7o8dwf61.png?width=2612&format=png&auto=webp&s=c069d60dfc3a424ae19c653ced14c4b03de4dfa8
Comparing FIRE to other major and small cap weed companies there is nothing overly concerning/amazing. Fire did post a loss in its most recent financial year of CA$139m and a latest trailing-twelve-month loss of CA$93m shrinking the gap between loss and breakeven. Note they did offer a big 100m fundraiser to generate capital for new partnerships, expansion.
I personally am of the belief that you need to attack to grow a business. Especially in crowded sectors such as Cannabis. I would rather see them look to create change and shake it up. You NEED to do something after having your market cap shrink as much as they have. Also keep in mind losses aren’t inherently bad as a company needs to invest to grow, but they do they to post positive earnings. They have their earnings coming up soon, so this is where momentum can change, if they can post a good quarter, I feel like the stock could explode. They are projected to grow 77.82% per year, plus the CEO has a good track record so it looks promising (more of that below).
But do note do not have a ton of cash to keep them fluid, so this earnings report is super important. They’ve missed their last four quarters and they need to start producing some profit.
Their earnings report will be announced Feb 11, 2021. People might be accumulating and generating hype on the hope of a good earnings report. This is similar to what happened with $SCR. Score absolutely blew up after they had a good earnings report after several consecutive quarters at a loss. Keep in mind this isn’t always the case (just look at AMD).
Summary: If you're willing to wager on this earnings reports being positive, this is nothing to worry about. If you're super adverse to risk, I would maybe stay away. Could be huge upside, but it is a gamble.

Team:

April 27, 2020 the company made a wise move, bringing in Beena The Beauty Goldenberg: Beena is now President & CEO of Supreme Cannabis Company. Goldenberg brings 30 years of CPG experience to her roles at Supreme. For the last 15 years, she worked in the natural and organics space. As the CEO of Hain-Celestial Canada, she grew the business from approximately $40 million to over $300 million by the time she left in 2020.
Here is a statement of Beena speaking pure fire about fire:

I joined Supreme Cannabis as President & CEO in April because I was drawn to the Company’s focus on quality – not just in our products, practices, and facilities – but in the emphasis our people place on continuous improvement across the organization. Since joining, I have seen us make significant progress in transforming ourselves into a premier cannabis CPG company.

It looks like Beena the beauty is in here to shake things up and bring some growth to this company. She noted that 2020 was a tough year for Cannabis growth, but it is clear a lot of investors are bullish on its opportunity in 2021. She came in and made some tough choices which I like, such as restructuring the organizational model, and adjusting the assumed valuations on parts of the business. Good to hear she made some cuts, shook things up and is looking to bring FIRE back to it’s 2018 hype.
I didn’t look into the rest of the team too much, they all look pretty run of the mill executives. If someone wants to look more into the team it would be appreciated.
Otherwise they have a 400 employee team everything looks pretty granola for the size of their operation.
Summary: In Beena the beauty we trust.

Now that you probably know more about FIRE than your degree, the big question is wether there is news to support the recent price action/drive up more in the future?

• Playing with B2B sales. They struck an agreement with Breath of Life International Ltd. to offer Truverra-branded premium medical cannabis to patients in Israel. To date, we have made three shipments of medical cannabis through the agreement. This “capitallight” approach further diversifies our revenue and builds Truverra as a global medical brand.
• ^ This is good because it shows they’re looking for international partners. This is where the real money is IMO, especially if legislation starts to change around the world regarding Cannabis products.
• Earnings on Feb 11
• ^ Gamble, I feel like it will be better, but if it isn’t great, I think the price will take a beating again. If it’s good 🚀
• I’m sure they’re seeking out more partners, opportunity for growth, new CEO is making the right moves. They just need to get their earnings up.
• Opportunity for mergers is another positive option.
• u/Hunterston noted that PepsiCo & Monsanto may have invested interests in the stock. He claims that BOL Pharma got their foot in the canadian market thru Supreme. supreme has sent 4 shipments to them and BOL afterwards sent a shipment to the UK with outstanding results. Potential shipments to Australia? I suspect we can learn a lot on the earnings call so we'll see if this is all true. This could further pump price action.

TDLR
Should you buy? I will buy. I am not comfortable YOLO’ing in this company but I feel like there is decent upside. It really depends on this earnings report, if you get in early you could get some great returns but you could also be investing in a dying company. They aren’t an insanely healthy company, so I would go into this with some skepticism. I have personally been looking for a decent weed play and I feel like this is as good as any for earning potential.
They have a product, earnings, and partnerships + plans, I can definitely see this company experiencing some growth. So much of this is dependant on earnings and it’s a decent company, but it isn’t really revolutionary. The weed sector is still new and so pillared to regulation. Governments are going to be looking for new $ after all the stimulus they’ve been giving so they should be more accepting of emerging sectors, but ultimately bureaucracy does what it will.
I’m not going to lie, one decent reason to buy is their branding. I can just see a lot of you shmelts getting fired up about FIRE because of the ticker and the company name supreme. I know this isn’t the most sound financial logic, but this is memorable and because of the low market cap, unique branding and potential, I can see it getting pumped by communities and P2P conversations.
I am not a financial advisor, make your own educated decisions, but I will likely be buying 5-10k shares to hold for a few years. Hopefully this helped 🚀 🚀 🚀

The cannabis market right now is so similar to the start of the green energy market.. its nowhere near done being bullish. Save for some small dips, there will very likely be a huge bullish trend for 2021. EVEN NASDAQ AGREES. I’ve posted my positions a few times, and I’ll continue to do so. But this is my reasoning for investing in cannabis stocks in general for 2021.

• I've been a bull on cannabis since the democrats had a strong pro-cannabis platform. But what made me go balls deep into the market was that the UN changed its classification of cannabis. Countries follow the UN closely for guidance on their own classification of controlled substances. Congress has repeatedly cited the UN’s classification as one of the reasons for not changing it. Several countries immediately changed their stance on cannabis in response to this, including Israel, which In November 2020, announced that it was moving forward with a plan to legalize recreational cannabis nationally. “The country is aiming to implement recreational legalization within nine months, and even if there are delays, that means mid-to-late 2021.” (This is my reason for investing in Canadian cannabis companies, because they are already poised to expand internationally since its legal there nationwide)

​

• THE SENATE IS NOW BLUE! The Georgia runoffs were won by Democrats, and they can now swing the vote left with VP Harris. She promised it as part of her platform, so we know it will be prioritized. CHUCK SHUMER SPONSORED THE MORE ACT. HE WILL BE SENATE MAJORITY LEADER. IT WILL 100% BE PRIORITIZED BETWEEN HIM AND VP HARRIS.

​

• EVERYONE predicted beforehand that the republicans would win Georgia... everyone talked down decriminalization passing the house because of they believed it would NEVER pass the republican majority senate. But the left spent more than any senate race in history to encourage voters to go out and vote. Only once the race started did it become clear that the left had a chance. Then some gains from the surprise that they won. However the gains from 1/5 onwards definitely hasn’t been priced in for all the future legislation, because some of it will be completely new legislation that wasn’t possible to consider before without a blue senate. THIS HASN'T BEEN PRICED INTO THE MARKET YET.

​

• The SAFE BANKING ACT has bipartisan support, and is likely to pass BEFORE decriminalization because it is tied into some stimulus bills.

​

• The government is broke post-COVID. There is a terrible image of the police. They don’t want to waste more resources on cannabis related crimes that would be fixed under decriminalization. And the tax revenue from decriminalization would be significant. Decriminalization (THE MORE ACT) opens up the borders to interstate-commerce and international import/export. This would all trickle down into Uncle Sam’s empty pockets.

​

• New York Governor Cuomo announced on Jan 6 his plan to legalize marijuana for adult use (right after New Jersey vote, as I anticipated in my last post) as part of his State of the State agenda. The next step is a ripple out on the North East. NY didn’t want to miss out on tax revenue, neither will any of the other states in the northeast within driving distance of NJ and NY. This is Cuomo’s third attempt in three years to legalize adult-use cannabis in the state; last year, Cuomo included a legalization proposal in his state budget, but the plan was ultimately cut in the wake of the COVID-19 pandemic.

Other ongoing state legislature:

• Rhode Island: Regulators have received 45 applications for six new medical cannabis dispensary licenses in the state. If all applicants meet the requirements for a license, six will randomly be selected in a lottery to operate retail locations in different regions across the state. Read more
• Missouri: Rep. Shamed Dogan has filed legislation that would place an adult-use cannabis legalization measure on the state’s 2022 ballot. Meanwhile, Missourians for a New Approach has announced plans for a separate 2022 ballot initiative after an unsuccessful signature campaign to get the issue before voters in 2020. Read more
• Alabama: Sen. Tim Melson plans to reintroduce a medical cannabis legalization bill this year. Medical cannabis legislation passed the Alabama Senate during the 2020 session, but failed to clear the House. Read more
• Illinois: Illinois lawmakers have proposed the creation of 75 new cannabis retail licenses to give disadvantaged and minority applicants a second chance at licensing following the controversial licensing lottery to issue an initial 75 dispensary licenses. A work group made up of lawmakers and members of Gov. J.B. Pritzker’s administration met this week to finalize details of the bill, which will be introduced in a lame-duck session that starts Jan. 8, before new lawmakers are sworn in Jan. 13. Read more
• Minnesota: House Majority Leader Ryan Winkler is again renewing his push to legalize adult-use cannabis in the state, announcing plans to reintroduce a legalization bill this year. Winkler told WCCO that he sees “Senate leadership as being the number one obstacle,” but said that if lawmakers agreed to place an adult-use legalization initiative on Minnesota’s 2022 ballot, “it would pass overwhelmingly.” Read more
• Virginia: Del. Steve Heretick has reintroduced a bill to legalize adult-use cannabis. Heretick has proposed legislation related to decriminalization and legalization in the past, and this year’s bill would legalize the cultivation, sale and consumption of cannabis in the state. Read more
• Connecticut: Gov. Ned Lamont renewed his push for adult-use legalization during his State of the State address Jan. 6, announcing that it is a priority for the new legislative session. Connecticut’s 2021 legislative session opened Jan. 6, and Lamont, a Democrat, kicks off the session with increased majorities in the House and Senate, which could increase his chances of passing an adult-use legalization bill. Read more

Now that you understand why I’m going green, here’s my reasoning for my positions.
TLRY (Tilray)

• largest cannabis company in the world by revenue post merger. Will run out of Seattle and New York City. New York Legalization on top of senate turning blue is a big catalyst for TLRY.
• Merger hasn’t completed yet, and the merger happened before the senate went blue.. that was the gamble APHA was making, and they won. The sky is the limit now. When they merge, they will reduce expenses and be much more likely to post profitable quarters. (This is why mergers have so much hype; the sum is > than their parts because they can reduce operating expenses while maintaining revenue from the two companies)
• Tilray CEO Brendan Kennedy: “I think medical cannabis will be legal at the federal level, which means medical cannabis can cross state lines and be imported into the U.S., like we export cannabis from Canada and Portugal to about 15 countries now,” Kennedy said. “Anyone who thinks there’s a state-specific medical market is wrong.” As for the recreational market, Kennedy says the state-specific markets, with interstate trade banned, “are not going to last long.” Kennedy believes that cannabis will be distributed like alcohol and tobacco within two years’ time. That would require significant overhaul of US federal drug laws—and would significantly disrupt all US cannabis companies’ existing business models. Brendan Kennedy, the cannabis billionaire will step down as Tilray's chairman and CEO. Irwin D. Simon, Aphria's current chairman and CEO will take Kennedy's place.
• [On December 18, 2020, just three days after the U.S. Senate adopted the Cannabidiol and Marihuana Research Expansion Act (CMREA or the Act) (more on this below), the U.S. Drug Enforcement Administration (DEA or the Administration) published in the Federal Register a final rule, “Controls To Enhance the Cultivation of Marihuana for Research in the United States” (Rule), which finally paves the way for DEA to issue additional licenses to grow “marihuana” (i.e., cannabis) for research purposes.](https://www.jdsupra.com/legalnews/on-heels-of-senate-s-adoption-of-36129/)

GNLN (Greenlane Holdings)

• One of the largest global sellers of premium cannabis accessories. Pax/JUUL/Volcano products. I’ve had Pax products, and although I prefer Arizer because of the affordability, I can’t deny Pax has quality products and is like the “iPhone” of vaporizers. I like their products, I like their branding. There’s lots of hype and loyalty, especially with their Volcano desktop vaporizer.
• Strong US brands.
• The main reason they did poorly was bad timing. They IPO’d during the year that JUULs started being banned. They’re actually at all those levels again. Theres a ton of upside potential.
• Market cap is ridiculously low for some really renown brands all because of the JUUL flavor pod ban. Everyone knows Pax, Volcano, and JUUL. But no one knows Greenlane because of the bad timing of their IPO and the subsequent JUUL flavor ban. It’s crazy. They’ve already broke all time high for the year. But I’m holding until they break 1B market cap.
• Recently became the exclusive distributor for the world's first gravity powered contactless water hookah.
• Overall i think too many people count it out just because of their IPO and subsequent decline in JUUL sales from the JUUL flavored pods ban. They definitely have the potential because of their strong branding and quality products. I’m betting on them having more high quality products in the future with equally loyal customers.

​
SNDL (Sundial Growers)

• SNDL must close above $1 per share for 10 consecutive sessions by June 26, 2021 or it will be delisted from NASDAQ. People see this as a fear factor, I see this as “they will do anything necessary to reach $1 for a week so they won’t be delisted”.. IMHO reverse splitter probably isn’t on the table since they could have done that in 2020, but instead applied for a 6 month extension after announcing “alternative strategic investments”. We can already see this by their predatory loan SPAC spinoff.
• Rumors of a merger with CGC; SNDL also purchased a SPAC recently and entered an agreement with Zenabis, immediately claiming they defaulted. Turning that SPAC into predatory loan/debt repurchasing company. Imo if they want to complete a merger, it would be easy to sell ownership through that SPAC to the buyer.
• THEY RECENTLY WENT DEBT FREE by selling off unprofitable assets in the business. This means we are much more likely to see earnings in future quarters, and they are much more attractive for mergers.
• Because they are indoor growers, they are more likely to be bought up by a company in the consolidating Canadian cannabis market than fail all together. The amount of space licensed to grow cannabis in Canada is now heavily skewed toward outdoor cultivation instead of indoor for the first time, according to new data from Health Canada. A growing population of licenses for outdoor growers means that there aren’t as many indoor licenses being given out... If a company ANYWHERE IN THE WORLD wants to quickly expand into indoor growing OR into the west, they would have to purchase an existing company that has the license to quickly do so. This is WAY faster, and a guaranteed way to obtain a license rather than applying for one and waiting x amount of months and be rejected for some requirement that wasn’t met.
• From my own experience, outdoor cannabis is subpar quality to indoor grown cannabis. So a growing market for outdoor cannabis doesn’t necessarily mean its better... it is likely just cheaper. I would imagine a high quality “craft cannabis” company would want to purchase SNDL, or an existing outdoor growing company that wants to quickly expand to indoor grown cannabis. With this being a Canadian company, there’s a chance a company in another country like Israel would be interested in purchasing it in the near future.

​
PLNHF (Planet 13 Holdings)

• Biggest tourist trap in Las Vegas if you’re a stoner, casual smoker, or just wanting to try it. From my own experience, I think they will continue to be successful. If I went around the US trying other brands I’d probably be more confident in putting 5-10% of my portfolio into those picks or choosing to not include them lol. Like for example, I used to have Curaleaf. But there's tons of bad feedback on Curaleaf, a friend has tried it said the nug is really subpar quality and if I tried their nug I’d probably confirm that I wouldn’t want to invest in them. With PLNHF, i’ve seen the ambience and tried the product myself. It’s definitely a lot of hype price wise, but still quality. This is my own bias showing, but I still think they’ve got solid fundamentals and excellent location/strong US branding.

​
I’m well aware of other good stocks like GTBIF, CRLBF, SSPK, TCNNF, GRWG.. but these stocks haven’t been swinging as hard in response to pro-cannabis news. E.g. TLRY, SNDL, GNLN swung more than 20% some days from pro-cannabis news...I will likely reduce my current positions shortly after inauguration, after some news about the timeline for cannabis legislation, and diversify my positions more between these other good picks.
​
2021 is the year of cannabis boys